Evidence map›Paper›PMID 22264238›Full record

ArticleBMC infectious diseases2012

HIV patients treated with low-dose prednisolone exhibit lower immune activation than untreated patients.

Christa Kasang, Albrecht Ulmer, Norbert Donhauser, Barbara Schmidt, August Stich, Hartwig Klinker, Samuel Kalluvya, Eleni Koutsilieri, Axel Rethwilm, Carsten Scheller

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Adjunct Therapy for CD4Frontiers in immunology · 2021
    Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. Rheumatoid arthritis in patients with HIV: management challenges.Open access rheumatology : research and reviews · 2016
    Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Christa KasangUniversity of Wuerzburg, Institute of Virology und Immunobiology, 97078 Wuerzburg, Germany.
Albrecht Ulmer
Norbert Donhauser
Barbara Schmidt
August Stich
Hartwig Klinker
Samuel Kalluvya
Eleni Koutsilieri
Axel Rethwilm
Carsten Scheller
University of Würzburg · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DEBugando Medical Centre · TZMedical Mission Institute · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHIV-associated general immune activation is a strong predictor for HIV disease progression, suggesting that chronic immune activation may drive HIV pathogenesis. Consequently, immunomodulating agents may decelerate HIV disease progression.

methodsIn an observational study, we determined immune activation in HIV patients receiving low-dose (5 mg/day) prednisolone with or without highly-active antiretroviral therapy (HAART) compared to patients without prednisolone treatment. Lymphocyte activation was determined by flow cytometry detecting expression of CD38 on CD8(+) T cells. The monocyte activation markers sCD14 and LPS binding protein (LBP) as well as inflammation markers soluble urokinase plasminogen activated receptor (suPAR) and sCD40L were determined from plasma by ELISA.

resultsCD38-expression on CD8+ T lymphocytes was significantly lower in prednisolone-treated patients compared to untreated patients (median 55.40% [percentile range 48.76-67.70] versus 73.34% [65.21-78.92], p = 0.0011, Mann-Whitney test). Similarly, we detected lower levels of sCD14 (3.6 μg/ml [2.78-5.12] vs. 6.11 μg/ml [4.58-7.70]; p = 0.0048), LBP (2.18 ng/ml [1.59-2.87] vs. 3.45 ng/ml [1.84-5.03]; p = 0.0386), suPAR antigen (2.17 μg/ml [1.65-2.81] vs. 2.56 μg/ml [2.24-4.26]; p = 0.0351) and a trend towards lower levels of sCD40L (2.70 pg/ml [1.90-4.00] vs. 3.60 pg/ml [2.95-5.30]; p = 0.0782). Viral load in both groups was similar (0.8 × 105 ng/ml [0.2-42.4 × 105] vs. 1.1 × 105 [0.5-12.2 × 105]; p = 0.3806). No effects attributable to prednisolone were observed when patients receiving HAART in combination with prednisolone were compared to patients who received HAART alone.

conclusionsPatients treated with low-dose prednisolone display significantly lower general immune activation than untreated patients. Further longitudinal studies are required to assess whether treatment with low-dose prednisolone translates into differences in HIV disease progression.

Indexed as

Acute-Phase ProteinsADP-ribosyl Cyclase 1AdultAnti-HIV AgentsCarrier ProteinsCD40 LigandCD8-Positive T-LymphocytesFemaleFlow CytometryHIV InfectionsHumansImmunologic FactorsImmunophenotypingLipopolysaccharide-Binding ProteinLipopolysaccharide ReceptorsLymphocyte ActivationAcute-Phase ProteinsADP-ribosyl Cyclase 1Anti-HIV AgentsCarrier ProteinsCD38 protein, humanCD40 LigandImmunologic FactorsLipopolysaccharide-Binding ProteinLipopolysaccharide ReceptorsMembrane GlycoproteinsPLAUR protein, humanPrednisoloneReceptors, Urokinase Plasminogen Activator

Identifiers

PMID22264238
PMCPMC3282641
OpenAlexW2151587606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.